Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dendreon Corporation has reported promising preliminary phase III results that show a prolonged survival benefit for prostate cancer patients treated with its drug Provenge.
Subscribe to our email newsletter
Patients were first treated with Provenge and then went on to receive docetaxel chemotherapy after disease progression.
The analysis evaluated survival data from 82 patients who received docetaxel chemotherapy following initial treatment with either Provenge or placebo. The median survival observed in the Provenge treated patients who subsequently received docetaxel was 34.5 months compared to 25.4 months for patients randomized to receive placebo who went on to receive docetaxel.
“This analysis provides valuable clinical insight as to how the treatment of men with advanced prostate cancer will likely evolve with the potential introduction of new products like sipuleucel-T that complement the currently available treatment regimens for men with advanced prostate cancer,” said Dr Petrylak, associate professor of medicine at the New York-Presbyterian Hospital at the Columbia University Medical Center.
Prostate cancer is the most common non-skin cancer in the US and the third most common cancer worldwide. More than one million men in the US have prostate cancer.